Myomectomy Market Forecasts to 2030 – Global Analysis By Product (Laparoscopic Power Morcellators, Laparoscopic Sealer, Harmonic Scalpel and Other Products), Type (Abdominal Myomectomy, Laparoscopic Myomectomy, Hysteroscopic Myomectomy and Robotic Myomect

Myomectomy Market Forecasts to 2030 – Global Analysis By Product (Laparoscopic Power Morcellators, Laparoscopic Sealer, Harmonic Scalpel and Other Products), Type (Abdominal Myomectomy, Laparoscopic Myomectomy, Hysteroscopic Myomectomy and Robotic Myomectomy ), End User and By Geography

According to Stratistics MRC, the Global Myomectomy Market is accounted for $756.59 million in 2023 and is expected to reach $1580.73 million by 2030 growing at a CAGR of 11.1% during the forecast period. A myomectomy is a surgical procedure aimed at removing noncancerous growths known as uterine fibroids from the muscular wall of the uterus. It is a viable alternative for women who want to avoid a hysterectomy or maintain their fertility. Furthermore, a number of techniques, such as open surgery, laparoscopy, and robotic-assisted surgery, can be used to carry out this procedure.

According to the Society for Women’s Health Research report, in the U.S. approximately 26 million women ages 15-50 have uterine fibroids.

Market Dynamics:

Driver:

Growing prevalence of uterine fibroids

Uterine fibroids are common benign tumours affecting a substantial number of women, particularly during their reproductive years. For instance, according to the Illinois Department of Public Health, around 77% of women of childbearing age may have uterine fibroids. Therefore, as more women have uterine fibroids diagnoses, there is a growing need for efficient treatment solutions to manage the resulting symptoms. Furthermore, minimally invasive techniques such as laparoscopy and robotic-assisted surgery are gaining popularity in myomectomy. This growing prevalence of uterine fibroids fuels the demand for myomectomy procedures, propelling the market's expansion

Restraint:

Fertility concerns

Myomectomy has the potential to affect fertility ability, even if the aim is to protect fertility by removing uterine fibroids. The surgical procedure, especially if multiple or large fibroids are removed, might lead to scarring or alterations in the uterus, potentially affecting reproductive capabilities. Women who wish to have children in the future are influenced by their concern about possible issues with their fertility after a myomectomy. This affects their decision-making process regarding treatment and may even restrict the market's expansion.

Opportunity:

Rising demand for minimally invasive procedures

Patients increasingly favour minimally invasive techniques like laparoscopic or robotic-assisted myomectomy due to reduced recovery times, less scarring, and a quicker return to daily activities. This growing preference aligns with the desire for effective yet less invasive treatments, especially among women seeking fertility preservation. Furthermore, healthcare providers offering these advanced procedures can attract more patients seeking myomectomy, addressing the rising demand for minimally invasive options and potentially expanding the market.

Threat:

Non-surgical alternatives

Advanced non-surgical treatments like uterine artery embolisation (UAE) or focused ultrasound surgery (FUS) offer effective options for treating uterine fibroids without surgery. The availability and increasing success rates of these non-surgical treatments pose a challenge to the traditional myomectomy market, potentially reducing the demand for surgical procedures and impacting the market's growth by offering compelling alternatives for fibroid management without surgical interventions.

Covid-19 Impact

The COVID-19 epidemic severely impacted women's healthcare and the market for myomectomy procedures. It caused delays in diagnosis and treatment, as well as the postponement of non-urgent treatments in the medical field. Also, interruptions in the supply chain impacted the accessibility of medical supplies required for myomectomy operations. In addition, hospitals diverted funds for COVID-19 therapy, which affected the focus on non-urgent medical operations. Consequently, COVID-19 limited the growth of the myomectomy market.

The laparoscopic myomectomy segment is expected to be the largest during the forecast period

The laparoscopic myomectomy segment is estimated to hold the largest share. Laparoscopic myomectomy involves a minimally invasive surgical procedure to remove uterine fibroids. This technique utilizes small incisions through which specialized instruments and a laparoscope are inserted, providing a magnified view of the uterus. Moreover, it offers benefits like shorter hospital stays, faster recuperation, and reduced postoperative complications. With increasing patient preference for minimally invasive options and advancements in laparoscopic techniques, this segment continues to gain traction as a preferred method for treating uterine fibroids.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to have lucrative growth during the forecast period. Hospitals and clinics equipped with advanced medical infrastructure and skilled healthcare professionals cater to patients seeking various treatment options for uterine fibroids. They offer comprehensive diagnostic evaluations, surgical expertise, and postoperative care, addressing patient needs with diverse surgical approaches such as laparoscopic, robotic-assisted, or open myomectomy procedures. In addition, hospitals and clinics play a pivotal role in delivering specialised care, contributing significantly to the accessible and comprehensive management of uterine fibroids through myomectomy.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the increasing number of women suffering from uterine disorders and the rising investment in the surgical device industry by key players in developing economies. China and Japan have played a significant role in the market expansion for myomectomy procedures. The supply of highly skilled medical personnel, including surgeons and gynaecologists, as well as the rising need for technologically sophisticated medical technologies, such as gene chips, for research purposes, are the main reasons for this growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the rising prevalence of uterine fibroid and technological advancements in myomectomy procedures. According to the data updated by the United States Office on Women's Health in February 2021, it was estimated that about 20 percent to 80 percent of women developed fibroids by the time they reached age 50. Women in their 40s and early 50s are most likely to develop uterine fibroids. While not all fibroids cause symptoms, those who do frequently find living with their fibroids to be difficult. Thus, the high burden of uterine fibroids in the United States is expected to boost market growth.

Key players in the market

Some of the key players in the Myomectomy Market include Medtronic, Conmed Corporation, Stryker Corporation, Insightec, Hologic, Inc, Cooper Surgical Inc, Intuitive Surgical, Braun Melsungen AG, Minerva Surgical Inc, Johnson And Johnson Services Inc., Karl Storz, Boston Scientific Corporation, General Electric Company, F. Hoffmann-La Roche Ltd, Richard Wolf Medical Instruments, Siemens, Bayer, AbbVie Inc. and Halt Medical, Inc.

Key Developments:

In November 2022, Olympus announced the market launch of the moresolution Power Morcellator, manufactured by TROKAMED GmbH and available in the United States through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. Olympus's pneumoLiner and the moresolution Morcellator can provide select patients with a laparoscopic surgical option.

In April 2022, Ethicon, part of Johnson & Johnson MedTech, launched the ENSEAL X1 Straight Jaw Tissue Sealer. The ENSEAL X1 Straight Jaw is indicated for use in open and laparoscopic general, gynecological, and urologic procedures.

Products Covered:
• Laparoscopic Power Morcellators
• Laparoscopic Sealer
• Harmonic Scalpel
• Other Products

Types Covered:
• Abdominal Myomectomy
• Laparoscopic Myomectomy
• Hysteroscopic Myomectomy
• Robotic Myomectomy

End Users Covered:
• Ambulatory Surgical Centers
• Hospitals & Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments

- Strategic recommendations for the new entrants

- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030

- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends

- Company profiling with detailed strategies, financials, and recent developments

- Supply chain trends mapping the latest technological advancements